Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Oct
03
Today In Oncology
FDA Approves First-Line Pirtobrutinib for CLL-SLL
Lung Cancer AI Model May Predict Pneumonitis Risk From Immunotherapy
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality
Are Narrower Negative Margins Linked to Higher Risk of DCIS Recurrence
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo